AHF Blasts Gilead Sciences, Inc. Price Hike on Four Key AIDS Drugs

Published: Jan 11, 2013

WASHINGTON--(BUSINESS WIRE)--Advocates from AIDS Healthcare Foundation (AHF) today criticized Gilead Sciences and its CEO John Martin on the news that effective January 1st, the company raised the price of eight drugs, including four key AIDS medications, which Gilead hiked an average of 6%. According to a recent Cowen Quick Take Distribution advisory from Cowen & Company, the financial and investment firm, ‘third party sources’ reported that Gilead’s bestselling three-in-one AIDS drug combination Atripla increased by 6.9% to a Wholesale Acquisition Cost (WAC) of $1,878.23 per patient, per month; Complera, by 5.8% to a WAC of $1,936.53; Emtriva by 5.5% to a WAC of $478.45 and Viread by 6.0% to a WAC of $771.39.

Back to news